Welcome to our dedicated page for Voyager Acqsn news (Ticker: VACHU), a resource for investors and traders seeking the latest updates and insights on Voyager Acqsn stock.
Voyager Acquisition Corp (VACHU) is a Cayman Islands exempted special purpose acquisition company (SPAC) whose units trade on the Nasdaq Global Market. As a blank check company, its key news events center on capital raising, trust account activity, and progress toward completing a business combination with an operating business.
News coverage for Voyager has included the pricing and closing of its initial public offering of units, which consist of Class A ordinary shares and redeemable warrants. These announcements detail the number of units offered, gross proceeds before expenses, and the expected separate listings for the Class A ordinary shares and warrants under the symbols VACH and VACHW.
A major news development for Voyager Acquisition Corp is the announcement of a definitive business combination agreement with VERAXA Biotech AG. This proposed transaction would create a publicly traded, clinical-stage biopharmaceutical company focused on a pipeline of next-generation cancer therapies. News related to this agreement covers the proposed equity value for VERAXA, the expected listing of the combined company under the ticker symbol VERX, and the anticipated timing of the closing, subject to shareholder approvals and customary conditions.
On this page, readers can follow press releases and other coverage related to Voyager’s SPAC lifecycle, including its initial public offering, the announced business combination with VERAXA, and subsequent regulatory and shareholder milestones. Investors and observers who track SPAC activity in the healthcare sector may find Voyager’s news flow useful for understanding the evolution of the proposed transaction and the structure of the units, shares, and warrants associated with VACHU.
VERAXA Biotech and Voyager Acquisition Corp (NASDAQ: VACH) have announced a definitive business combination agreement valued at a pre-money equity value of $1.3 billion. The merger will create a Nasdaq-listed biopharmaceutical company focused on next-generation cancer therapies.
The combined entity will trade under ticker VERX and have access to up to $253 million in cash held in trust. VERAXA's proprietary BiTAC platform develops novel cancer therapies, including Antibody-Drug Conjugates (ADCs) and Bispecific T-cell Engagers (TCEs). Their pipeline includes nine development programs, with VX-A901 already in Phase 1 trials for leukemia.
The transaction is expected to close in Q4 2025, subject to shareholder approval. VERAXA is also raising a crossover financing round expected to close before the business combination. The global market potential is significant, with TCE market projected to reach $112 billion by 2030 (CAGR >44%) and ADC market expected to hit $57 billion by 2030 (CAGR ~30%).
Voyager Acquisition Corp. (Nasdaq: VACHU) announced that holders of units from its initial public offering can now separately trade Class A ordinary shares and warrants starting around September 30, 2024. The company's IPO, completed on August 12, 2024, involved 25,300,000 units, including 3,300,000 from the underwriters' overallotment option.
Unseparated units will continue trading as 'VACHU' on Nasdaq, while separated Class A shares and warrants will trade under 'VACH' and 'VACHW' respectively. Only whole warrants will trade, and unit holders must contact Continental Stock Transfer & Trust Company to separate their units.
Voyager Acquisition Corp. is a Cayman Islands-based blank check company seeking business combinations. The securities registration became effective on August 8, 2024. This announcement does not constitute an offer to sell or solicit offers to buy these securities.
Voyager Acquisition Corp. (Nasdaq: VACHU) has successfully closed its initial public offering, raising $253 million in gross proceeds. The company sold 25,300,000 units at $10.00 per unit, including the full exercise of the underwriters' over-allotment option. Each unit comprises one Class A ordinary share and one-half of a redeemable warrant. The units began trading on the Nasdaq Global Market on August 9, 2024, under the ticker symbol 'VACHU'. Voyager Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aiming to pursue a business combination in the future. Cantor Fitzgerald & Co. served as the sole book-running manager, with Odeon Capital Group as co-manager for the offering.
Voyager Acquisition Corp. (Nasdaq: VACHU) has announced the pricing of its initial public offering (IPO) of 22,000,000 units at $10.00 per unit, totaling $220,000,000. The units are expected to begin trading on the Nasdaq Global Market under the ticker symbol 'VACHU' on August 9, 2024. Each unit comprises one Class A ordinary share and one-half of one redeemable warrant.
The underwriters have a 45-day option to purchase up to an additional 3,300,000 units to cover over-allotments. Cantor Fitzgerald & Co. is the sole book-running manager, with Odeon Capital Group as co-manager. The offering is expected to close on August 12, 2024, subject to customary conditions.
Voyager Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aiming to pursue a business combination in the future.